Nicolas Floc’h

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

Min Zou, Roxanne Toivanen, Antonina Mitrofanova et al. · Cancer Discovery · 2017 · 394 citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess et al. · Molecular Cancer Therapeutics · 2018 · 111 citations · Full text

Medicine, Oncology, Pharmacology +16

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

Eric Tu, Kelly McGlinchey, Jixin Wang et al. · JCI Insight · 2022 · 109 citations · Full text

Life Sciences, Immunology, Oncology +17

B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer

Jingqiang Wang, Takashi Kobayashi, Nicolas Floc’h et al. · Cancer Research · 2012 · 92 citations · Full text

Medicine, Molecular Biology, Oncology +17

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

Nicolas Floc’h, Carolyn Waugh Kinkade, Takashi Kobayashi et al. · Cancer Research · 2012 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17